It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Discover various work from home opportunities that can provide you with fast money. These options cater to different skills and schedules.
19,997 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As July 18, 2026 approaches, the GENIUS Act deadline accelerates rulemaking for stablecoin issuers. Regulators from T...
A simple, durable approach to building income: three passive income ETFs worth holding for the long haul. Learn how t...
The Virtus InfraCap U.S. Preferred Stock ETF trades near $21 with a 9.9% forward yield built on leverage and high-cou...
President Trump signed proclamations shrinking Bears Ears and Grand Staircase-Escalante monuments by roughly 90%, sig...
XYLD has delivered steady income, yet its upside is capped. This analysis details the hidden costs and current perfor...
A London court sentenced seven people for a $5.4 million crypto scam that used fake police branding to steal digital ...
As market volatility lingers in 2026, the timing of Social Security claims tied to birthdays can dramatically alter m...
The Roundhill Magnificent Seven ETF has delivered strong gains since its April 2023 start, but a growing concentratio...
A modest Tuesday gain for SPGI helped the stock beat the broad market's small rise. This piece explains what a global...
What strategy (MSTR)? bitcoin has become a touchstone for corporate crypto bets. This article explains the concept, t...
A simple, time-tested approach often beats chasing hot sectors. Learn why a broad-market ETF could be your winning mo...